1. Home
  2. CBRL vs CGEM Comparison

CBRL vs CGEM Comparison

Compare CBRL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cracker Barrel Old Country Store Inc

CBRL

Cracker Barrel Old Country Store Inc

N/A

Current Price

$27.57

Market Cap

694.2M

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$14.02

Market Cap

780.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBRL
CGEM
Founded
1969
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
694.2M
780.4M
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
CBRL
CGEM
Price
$27.57
$14.02
Analyst Decision
Hold
Strong Buy
Analyst Count
8
9
Target Price
$37.75
$30.11
AVG Volume (30 Days)
1.1M
781.2K
Earning Date
06-04-2026
05-29-2026
Dividend Yield
3.59%
N/A
EPS Growth
12.57
N/A
EPS
N/A
N/A
Revenue
$3,030,445,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.56
N/A
52 Week Low
$24.85
$5.68
52 Week High
$68.09
$16.74

Technical Indicators

Market Signals
Indicator
CBRL
CGEM
Relative Strength Index (RSI) 34.50 49.92
Support Level $25.24 $6.65
Resistance Level $29.73 $16.74
Average True Range (ATR) 1.73 1.00
MACD -0.55 -0.19
Stochastic Oscillator 3.98 14.24

Price Performance

Historical Comparison
CBRL
CGEM

About CBRL Cracker Barrel Old Country Store Inc

Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: